{
    "clinical_study": {
        "@rank": "48411", 
        "acronym": "HARMONY", 
        "arm_group": [
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Anti hypertensive medication in the evening (between 18.00 and 23.00)"
            }, 
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "Antihypertensive medication in the morning(between 06.00 and 11.00)"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomised crossover trial of anti-hypertensive medication dosing regimen in effective\n      blood pressure control.\n\n      To investigate whether there is a difference in 24 hour blood pressure (BP) control when\n      antihypertensive medications are taken in the morning compared with the evening. The\n      identification of any significant difference could lead to more effective therapeutic\n      management of arterial hypertension, which in turn would result in a reduced cardiovascular\n      burden, lower costs and a better quality of life for hypertensive patients."
        }, 
        "brief_title": "Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian patients aged 18-80 years;\n\n          -  History of any grade of hypertension for at least 1 year, including at      least 3\n             months of constant antihypertensive medication (consisting of \u2265 1 antihypertensive\n             drugs, each administered in one dose daily), with reasonably controlled BP (\u2264150/90\n             mmHg and \u2265 115/75 mmHg on usual medication) based on previous clinic records, in the\n             last 3 months.\n\n        Exclusion Criteria:\n\n          -  BP levels > 150/90 mmHg or < 115/75 mmHg in the last 3 months.\n\n          -  Postural hypotension, defined as symptoms resulting from a > 20 mm Hg drop of\n             systolic BP or a > 10 mm Hg drop of diastolic BP or both between 1 and 3 min after\n             standing from the sitting position.\n\n          -  Known Extreme  dippers at baseline (fall of mean night time SBP > 20% of mean day\n             time SBP)\n\n          -  Individuals with jobs which require night-time shift work.\n\n          -  Pregnant women or those planning to become pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669928", 
            "org_study_id": "CRO1749"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group B", 
                "Group A"
            ], 
            "description": "Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.\nDosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).", 
            "intervention_name": "Anti-hypertensive Medication -", 
            "intervention_type": "Drug", 
            "other_name": [
                "PR1 Diruetics", 
                "PR3 Beta Blockers", 
                "PR4 Calcium channel blockers", 
                "PR5 ACE inhibitors", 
                "PR6 Angiotensin II Receptor Blockers", 
                "PR7 Centrally acting agents", 
                "PR8 Alpha blockers", 
                "PR9 Direct Renin Inhibitors", 
                "PR10 Vasodilators"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin II", 
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Antihypertensive Agents", 
                "Calcium Channel Blockers", 
                "Vasodilator Agents", 
                "Angiotensin Receptor Antagonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 17, 2012", 
        "location": [
            {
                "contact": {
                    "email": "a.hatzitolios@imperial.ac.uk", 
                    "last_name": "Apostolos Hatzitolios", 
                    "phone": "+ 30 2310994783"
                }, 
                "contact_backup": {
                    "email": "c.savopoulos@imperial.ac.uk", 
                    "last_name": "Christos Savopoulos"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "Aristotle University of Thessaloniki"
                }, 
                "investigator": [
                    {
                        "last_name": "Apostolos Hatzitolios", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Cristos Savopoulos", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W2 1LA"
                    }, 
                    "name": "Imperial Clinical Trials Unit"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Hellenic Anglo Research Into Morning Or Evening Antihypertensive Drug deliverY Trial", 
        "overall_contact": {
            "email": "n.thirunavukkarasu@imperial.ac.uk", 
            "last_name": "Neeraja Thirunavukkarasu, MSc", 
            "phone": "+44 2075941330"
        }, 
        "overall_official": {
            "affiliation": "Imperial College London", 
            "last_name": "Neil Poulter, MRCS LRCP MBBS MRCP MSc FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "3mm Hg difference in mean 24 hour systolic Blood Pressure", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "reference": [
            {
                "PMID": "7656688", 
                "citation": "Lemmer B. Clinical chronopharmacology: the importance of time in drug treatment. Ciba Found Symp. 1995;183:235-47; discussion 247-53. Review."
            }, 
            {
                "PMID": "9739478", 
                "citation": "Bruguerolle B. Chronopharmacokinetics. Current status. Clin Pharmacokinet. 1998 Aug;35(2):83-94. Review."
            }, 
            {
                "PMID": "20226988", 
                "citation": "Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahl\u00f6f B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X."
            }, 
            {
                "PMID": "20571367", 
                "citation": "Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010 Aug;15(4):173-80. doi: 10.1097/MBP.0b013e32833c7308. Review."
            }, 
            {
                "PMID": "20854139", 
                "citation": "Hermida RC, Ayala DE, Moj\u00f3n A, Fern\u00e1ndez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010 Sep;27(8):1629-51."
            }, 
            {
                "PMID": "10639539", 
                "citation": "Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748."
            }, 
            {
                "PMID": "9576134", 
                "citation": "Mayet J, Chapman N, Li CK, Shahi M, Poulter NR, Sever PS, Foale RA, Thom SA. Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension. 1998 May;31(5):1190-4."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean day-time ABPM systolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Mean day-time ABPM diastolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "\u039cean night time  ABPM systolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "\u039cean night time  ABPM diastolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Mean clinic - systolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Mean clinic - diastolic BP", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Concordance with taking drug treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Self reported side effects", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Clinical events (extra GP or hospital visits and procedures and hospitalization)", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Imperial College London", 
        "sponsors": {
            "collaborator": {
                "agency": "Aristotle University Of Thessaloniki", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Imperial College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}